This is an aggregated industry headline. Read the full story at PharmaVoice →
Will obesity drugs save Pfizer from its post-COVID slump?
With COVID's windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline.
By PharmaVoice
· Jun 9, 2026
· via PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squib…
The WeekFierceBiotech ↗
Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another roun…
The WeekBriefing
Eli Lilly, Biogen, Eisai, and Genentech sponsor a new Alzheimer’s-focused podcast as pharma marketing leans de…